Physician profile
Jennifer E Leonida
NPI 1003189093
$2,352.35
in general payments reported to CMS, 2019-2025
27 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $402 · 2023: $531 · 2024: $543 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.23 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $548.50 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $440.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.33 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Vanda Pharmaceuticals INC. | $182.25 | 2024-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $152.82 | 2021-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $138.21 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Pfizer INC. | $106.61 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.04 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $84.11 | 2024 | Veozah |
| Glaxosmithkline, LLC. | $56.37 | 2021-2022 | |
| Axsome Therapeutics, INC. | $42.57 | 2025 | Auvelity |
| Amarin Pharma, INC. | $37.57 | 2021-2022 | |
| Amgen INC. | $33.45 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $32.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.94 | 2022-2023 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.19 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.59 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.36 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.11 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $15.94 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.49 | 2022 | |
| Exact Sciences Corporation | $13.41 | 2023 | Cologuard Collection Kit |
| Vbi Vaccine (Delaware) INC. | $12.71 | 2022 | |
| Merck Sharp & Dohme LLC | $12.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.89 | 2022 | |
| Theracosbio, LLC | $8.35 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Leonida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.